Cerebral microbleeds are tiny bleedings in the brain linked to stroke, dementia and age-related cognitive decline. Understanding how and why they develop is essential for preventing long-term brain damage. However, progress has been limited by the lack of animal models. This research developed a new rat model using a compound called RAME-CD to induce CMBs in a controlled way, allowing scientists to study their consequences and test treatments more effectively. The societal impact of this work extends across several sectors. In public health and clinical medicine, the model could help identify who is most at risk of CMB-related complications. This could guide more personalized and safer treatment strategies, ultimately reducing stroke and dementia rates. For the pharmaceutical and biotech industries, the model offers a valuable tool to develop and test new drugs that protect blood vessels or slow brain degeneration. Stakeholders include medical doctors, patients, caregivers and pharmaceutical developers focused on aging, dementia, and stroke prevention. Non-profit groups may use findings from this research to push for better screening and awareness of small vessel disease. While still at the early research stage, this model paves the way for real-world applications that could improve quality of life for millions, especially as populations age. It also supports global efforts in brain health research, with the potential to reduce healthcare costs and improve care for individuals at risk of cerebrovascular diseases.